Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-137438

Published: 2020

Journal Articles

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136265

Published: 2020

Journal Articles

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

Jun-ichi Nishimura, MD PhD, Kensuke Usuki, MD PhD, Julia Ramos, MD PhD, Satoshi Ichikawa, MD PhD, Jules Hernández-Sánchez, PhD, Anna Kiialainen, PhD, Alexandre Sostelly, PhD, Regis Peffault De Latour, MD PhD, Ido Paz-Priel, MD, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136048

Published: 2020

Journal Articles

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Regis Peffault De Latour, MD PhD, Simona Sica, MD PhD, Julia Ramos, MD, Jules Hernández-Sánchez, PhD, Jin Seok Kim, MD PhD, Anna Kiialainen, PhD, Sung-Soo Yoon, MD PhD, Sasha Sreckovic, MD, Antoine Soubret, PhD, Haruhiko Ninomiya, MD PhD, Alexandre Sostelly, PhD, Jens Panse, MD, Simon Buatois, PharmD, PhD, Hubert Schrezenmeier, Ido Paz-Priel, MD, Jun-ichi Nishimura, MD PhD, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-135841

Published: 2020

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Victor Jimenez-Yuste, Midori Shima, MD PhD, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 1187.

https://doi.org/10.1182/blood-2018-99-118132

Published: 2018

Journal Articles

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz-Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt

Blood (2018) 132 (Supplement 1): 633.

https://doi.org/10.1182/blood-2018-99-118492

Published: 2018

Journal Articles

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Alexander Roeth, MD, Nagy Zsolt, MD PhD, Miklos Egyed, MD, Erica Winter, Joy Hsu, Andreas Dieckmann, Judith Anzures-Cabrera, Marie Mannino, Elana Fernandez, PhD, Gregor Jordan, Barbara Klughammer, PhD, Kenji Shinomiya, Naoki Kotani, Ido Paz-Priel, MD, Angelika Jahreis., MD, PhD

Blood (2017) 130 (Supplement 1): 4750.

https://doi.org/10.1182/blood.V130.Suppl_1.4750.4750

Published: 2017

Journal Articles

Loss of IKKβ Increases the Number and Self-Renewal Capacity of Hematopoietic Stem Cells

Jing Zhang, PhD, Li Li, PhD, Albert S. Baldwin, PhD, Alan D. Friedman, MD, Ido Paz-Priel, MD

Blood (2014) 124 (21): 4345.

https://doi.org/10.1182/blood.V124.21.4345.4345

Published: 2014

Journal Articles

Canonical NF-κB Signalling Is a Potential Target in FLT3/ITD AML.

Jing Zhang, PhD, Li Li, PhD, Alan D. Friedman, M.D., Donald Small, MD, PhD, Ido Paz-Priel, M.D.

Blood (2012) 120 (21): 2447.

https://doi.org/10.1182/blood.V120.21.2447.2447

Published: 2012

Journal Articles

C/EBPα and C/EBPα oncoproteins regulate nfkb1 and displace histone deacetylases from NF-κB p50 homodimers to induce NF-κB target genes

Ido Paz-Priel, Simone Houng, Julia Dooher, Alan D. Friedman

Blood (2011) 117 (15): 4085–4094.

https://doi.org/10.1182/blood-2010-07-294470

Published: 2011

Journal Articles

NF-κB Target Genes Activation Via Displacement of HDACs Bound to NF-κB p50 Homodimers by C/EBPα, Its AML Oncoproteins or C/EBPβ.

Ido Paz-Priel, M.D., Simone Houng, M.Eng., Julia E. Dooher, Ph.D., Alan D. Friedman, M.D.

Blood (2010) 116 (21): 3637.

https://doi.org/10.1182/blood.V116.21.3637.3637

Published: 2010

Journal Articles

C/EBPα, C/EBPα Oncoproteins, or C/EBPβ Preferentially Bind NF-κB p50 Compared with p65 Via Conserved Residues In the C/EBP Basic Region

Julia E. Dooher, Ph.D., Ido Paz-Priel, M.D., Simone Houng, Albert S. Baldwin, Jr., Ph.D., Alan D. Friedman, M.D.

Blood (2010) 116 (21): 708.

https://doi.org/10.1182/blood.V116.21.708.708

Published: 2010

Journal Articles

C/EBPα or Its Leukemic Mutants Directly Activate nfkb1 Transcription and Displace HDAC1 or HDAC3 From Chromatin-Associated NF-κB p50 to Induce Anti-Apoptotic Genes.

Ido Paz-Priel, MD, Alan D. Friedman, MD

Blood (2009) 114 (22): 76.

https://doi.org/10.1182/blood.V114.22.76.76

Published: 2009

Journal Articles

C/Ebpβ Inhibits Apoptosis in Hematopoietic Cells Via Interaction with NF-κb p50.

Rebecca McFall, MD, Ido Paz-Priel, MD, Alan D. Friedman, MD

Blood (2008) 112 (11): 1332.

https://doi.org/10.1182/blood.V112.11.1332.1332

Published: 2008

Journal Articles

A Positive Feedback Loop Between C/EBPα and NF-κB p50 Inhibits Both the Intrinsic and Extrinsic Apoptosis Pathways

Ido Paz-Priel, MD, Dehua Wang, MD, Alokesh Ghosal, Ph.D., Alan D. Friedman, M.D.

Blood (2008) 112 (11): 501.

https://doi.org/10.1182/blood.V112.11.501.501

Published: 2008

Journal Articles

C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment

Christine Yeamans, Dehua Wang, Ido Paz-Priel, Bruce E. Torbett, Daniel G. Tenen, Alan D. Friedman

Blood (2007) 110 (9): 3136–3142.

https://doi.org/10.1182/blood-2007-03-080291

Published: 2007

Journal Articles

C/EBPα Binds and Activates the Distal PU.1 Enhancer.

Christine Yeamans, MD, Dehua Wang, MD, MS, Ido Paz-Priel, MD, Daniel G. Tenen, MD, Alan D. Friedman, MD

Blood (2006) 108 (11): 1176.

https://doi.org/10.1182/blood.V108.11.1176.1176

Published: 2006

Journal Articles

C/EBPα and C/EBPα Myeloid Oncoproteins Induce Bcl-2 Via Interaction of Their Basic Regions with NF-κB p50.

Ido Paz-Priel, Dong Hong Cai, Dehua Wang, Jeanne Kowalski, Amanda Blackford, Huaitian Liu, Caroline A. Heckman, Adrian F. Gombart, H. Phillip Koeffler, Linda M. Boxer, Alan D. Friedman

Blood (2005) 106 (11): 2992.

https://doi.org/10.1182/blood.V106.11.2992.2992

Published: 2005

NARROW

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Loss of IKKβ Increases the Number and Self-Renewal Capacity of Hematopoietic Stem Cells

Canonical NF-κB Signalling Is a Potential Target in FLT3/ITD AML.

C/EBPα and C/EBPα oncoproteins regulate nfkb1 and displace histone deacetylases from NF-κB p50 homodimers to induce NF-κB target genes

NF-κB Target Genes Activation Via Displacement of HDACs Bound to NF-κB p50 Homodimers by C/EBPα, Its AML Oncoproteins or C/EBPβ.

C/EBPα, C/EBPα Oncoproteins, or C/EBPβ Preferentially Bind NF-κB p50 Compared with p65 Via Conserved Residues In the C/EBP Basic Region

C/EBPα or Its Leukemic Mutants Directly Activate nfkb1 Transcription and Displace HDAC1 or HDAC3 From Chromatin-Associated NF-κB p50 to Induce Anti-Apoptotic Genes.

C/Ebpβ Inhibits Apoptosis in Hematopoietic Cells Via Interaction with NF-κb p50.

A Positive Feedback Loop Between C/EBPα and NF-κB p50 Inhibits Both the Intrinsic and Extrinsic Apoptosis Pathways

C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment

C/EBPα Binds and Activates the Distal PU.1 Enhancer.

C/EBPα and C/EBPα Myeloid Oncoproteins Induce Bcl-2 Via Interaction of Their Basic Regions with NF-κB p50.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only